A Study to Assess Deucravacitinib Safety in Pregnancy

Study Summary

The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.

Conditions

Psoriasis (PsO)

Interventions / Drugs

Deucravacitinib Other systemic treatments for PsO

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment900 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.746086+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.